FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* LAPOINTE ANTHONY GREGG			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner						
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.			3. Date of Earliest Transaction (Month/Day/Year) 05/20/2022						-	Officer (give	e title below)	Oth	er (specify bel	ow)	
(Street) SOUTH SAN FRANCISCO, CA 94080			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City		(State)	(Zip)			Гable I	- Non-Dei	ivative Se	curities	s Acquire	ed, Disposed	of, or Bene	ficially Own	ed	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date, if		3. Transaction Code (Instr. 8)		I. Securities Acquired A) or Disposed of (D) Instr. 3, 4 and 5)		aired 5 of (D) C	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		eneficially ed	6. Ownership Form:	Beneficial	
				(Month/	Day/Year)	Cod	le V	Amount	(A) or (D)	Price	or I		Direct (D) or Indirect (I) (Instr. 4)	Indirect (Instr. 4)	
Common	Stock		05/20/2022			A		25,000 (1)	A	\$ 0 5	0 50,000			D	
Reminder:	Report on a s	separate line for each	1 class of securities l	beneficial	ly owned d	irectly o	Perso in this	ns who re form are	not re	equired	collection o to respond IB control n	unless the		ned SEC	1474 (9-02)
Reminder:	Report on a s	separate line for eacl	1 class of securities l	beneficial	ly owned d	irectly o	Perso in this	ns who re form are	not re	equired	to respond	unless the		ned SEC	1474 (9-02)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	Derivativ (e.g., put: 4. Transacti Code	ve Securiti s, calls, wa 5. Nur of Der Securi	nber ivative ties red (A) posed	Perso in this displa uired, Disp	ns who re form are ys a curr posed of, o onvertible tercisable a	e not reently ver Benefice securional	equired to a sequired to a sequired to a sequired to a sequired to a sequire to a sequire to a sequire to a sequire	to respond IB control n Owned and Amount rlying es	unless the umber.	9. Number o	of 10. Owners Form o	11. Nat hip of Indir f Benefic ive Owners y: (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivativ (e.g., put: 4. Transacti Code	ve Securiti s, calls, wa 5. Nur ion of Der Securi Acquir or Dis	des Acquarrants, inber ivative ties red (A) posed 3, 4,	Perso in this displa uired, Dispoptions, c 6. Date Expiration (Month/D	ns who reform are ys a curre cosed of, o convertible cercisable a Date aay/Year)	e not re ently v r Benet e securi	required (valid OM ficially Ofties) 7. Title a of Under Securitie (Instr. 3	to respond IB control n Owned and Amount rlying es and 4)	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	of 10. Owners Form o Derivat Security Direct (or Indir	11. Nat bip of Indir f Benefic ive Owners (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivativ (e.g., put: 4. Transacti Code	ve Securiti s, calls, wa of Der Securi Acqui or Dis of (D) (Instr.	des Acquarrants, inber ivative ties red (A) posed 3, 4,	Perso in this displa	ns who reform are ys a curre cosed of, o convertible cercisable a Date aay/Year)	e not re ently v r Benet e securi	equired to valid OM ficially Oties) 7. Title a of Under Securitie	to respond IB control n Owned and Amount rlying es and 4)	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form o Derivat Security Direct (or Indir (s) (I)	11. Nat bip of Indir f Benefic ive Owners (Instr. 4

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
LAPOINTE ANTHONY GREGG RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/23/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
- (2) The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.